O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants

Neuropsychopharmacology

Volumn 20, Issue 5, 1999, Pages 480-490

  Fogelman, Steven M ^a   Schmider, J ürgen ^a   Venkatakrishnan, Karthik ^a   Von Moltke, Lisa L ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P 450; Selective serotonin reuptake inhibitors; Venlafaxine

Indexed keywords

CYTOCHROME P450; FLUOXETINE; N DEMETHYLASE; NORFLUOXETINE; NORSERTRALINE; O DEMETHYLASE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DNA TRANSFECTION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES; BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEALKYLATION; DNA, COMPLEMENTARY; HUMANS; KINETICS; MICROSOMES, LIVER; RABBITS; RATS; SEROTONIN UPTAKE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET; TRANSFECTION;

EID: 0033136981     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00113-4     Document Type: Article

References (31)

1. Ball S.E., Ahern D., Scatina J., Kao J. Venlafaxine. In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2 Br J Clin Pharmacol. 43:1997;619-626.
2. Belpaire F.M., Wijnant P., Temmerman A., Rasmussen B.B., Brosen K. The oxidative metabolism of metoprolol in human liver microsomes. Inhibition by the selective serotonin reuptake inhibitors Eur J Clin Pharmacol. 54:1998;261-264.
3. Crespi C.L. Xenobiotic - metabolizing human cells as tools for pharmacological and toxicological research. Advances Drug Res. 26:1995;179-235.
4. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 34:1992;262-265.
5. Cunningham L.A., Borison R.L., Carman J.S., Chouinard G., Crowder J.E., Diamond B.I., Fischer D.E., Hearst E. A comparison of venlafaxine, trazadone, and placebo in major depression. J Clin Psychopharm. 14:1994;99-106.
6. Findling R.L., Schwartz M.A., Flannery D.J., Manos M.J. Venlafaxine in adults with attention-deficit/hyperactivity disorder. an open clinical trial J Clin Psych. 57:1996;184-189.
7. Geracioti T.D. Venlafaxine treatment of panic disorder. A case series J Clin Psych. 56:1995;408-410.
8. Kobayashi K., Chiba K., Yagi T., Shimada N., Taniguchi T., Horie T., Tani M., Yamamoto T., Ishizaki T., Kuroiwa Y. Identification of cytochrome P450 isoforms involved in citalopram N-demthylation by human liver microsome. JPET. 280:1997;927-933.
9. Motulsky H.J., Ransnas L.A. Fitting curves to data using nonlinear regression. A practical and nonmathematical review FASEB. 1:1987;365-374.
10. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielsen S.T., Sig E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 5:1986;4493-4497.
11. Muth E.A., Moyer J.A., Haskins J.T. Biochemical, neurophysiological, and behavioral effects of WY-45, 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 23:1991;191-199.
12. Newton D.J., Wang R.W., Lu A.Y.H. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes Drug Metab Dispos. 23:1995;154-158.
13. Nielsen K.K., Flinois J.P., Beaune P., Brosen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 77:1996;1659-1664.
14. Norby J, Rubenstein S, Tuerke T, Farmer S, Forood R, Bennington J (1991): Sigma Plot, v. 2.00. Jandel Corporation.
15. Otton S.V., Ball S.E., Cheung S.W., Inaba T., Rudolph R.L., Sellers E.M. Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br J Clin Pharmacol. 41:1996;149-156.
16. Otton S.V., Wu D., Joffe R.T., Cheung S.W., Sellers E.M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 53:1993;401-409.
17. Ring B.J., Binkley S.N., Roskos L., Wrighton S.A. Effect of fluoxetine, norfluoxetine, sertraline, and desmethylsertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther. 275:1995;1131-1135.
18. Schmider J., Greenblatt D.J., Harmatz J.S., Shader R.I. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions. application to amitriptyline N-demethylation Br J Clin Pharmacol. 41:1996;593-604.
19. Schmider J., Greenblatt D.J., von Moltke L.L., Harmatz J.S., Shader R.I. N-demethylation of amitriptyline in vitro. Role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors J Pharmacol Exp Ther. 275:1995;592-597.
20. Schweizer E., Feighner J., Mandos L.A., Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psych. 55:1994;104-108.
21. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. Studies with liver microsomes of 30 Japanese and 30 Caucasians JPET. 270:1994;414-423.
22. Skjelbo E., Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 34:1992;256-261.
23. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro. Dominance of CYP2C19 and 3A4 J Clin Pharmacol. 38:1998;112-121. a.
24. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes. application of the relative activity factor approach J Pharm Sci. 87:1998;845-853. b.
25. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole. A model system to predict drug interactions in vivo J Pharmacol Exp Ther. 268:1994;1278-1283.
26. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine. Comparison with other selective serotonin reuptake inhibitor antidepressants J Clin Psychopharm. 15:1995;125-131.
27. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Venkatakrishnan K., Schmider J., Harmatz J.S., Shader R.I. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro. Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A J Pharm Pharmacol. 50:1998;997-1004.
28. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Shader R.I. Alprazolam metabolism in vitro. Studies of human, monkey, mouse, and rat liver microsomes Pharmacology. 47:1993;268-276.
29. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Duan S.X., Harrel L.M., Cotreau-Bibbo M.M., Pritchard G.A., Wright C.E., Shader R.I. Triazolam biotransformation by human liver microsomes in vitro. Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. 276:1996;370-379. a.
30. von Moltke L.L., Greenblatt D.J., Duan S.X., Harmatz J.S., Wright C.E., Shader R.I. Inhibition of terfenadine metabolism in vitro by azole antifungals agents and by selective serotonin reuptake inhibitor antidepressants. Relation to pharmacokinetic interactions in vivo J Clin Psychopharmacol. 16:1996;104-112. b.
31. von Moltke L.L., Greenblatt D.J., Schmider J., Duan S.X., Wright C.E., Harmatz J.S., Shader R.I. Midazolam hydroxylation by human liver microsomes in vitro. Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents J Clin Pharmacol. 36:1996;783-791. c.